Synergy Pharmaceuticals (SGYP) : Traders are bullish on Synergy Pharmaceuticals (SGYP) as it has outperformed the S&P 500 by a wide margin of 2% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 2.07%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 2% in the last 1 week, and is up 5.43% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
The stock has recorded a 20-day Moving Average of 4.16% and the 50-Day Moving Average is 8.26%. Synergy Pharmaceuticals, Inc. is up 29.94% in the last 3-month period. Year-to-Date the stock performance stands at -28.04%.
Synergy Pharmaceuticals (NASDAQ:SGYP): On Fridays trading session , Opening price of the stock was $4.12 with an intraday high of $4.14. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $4.05. However, the stock managed to close at $4.08, a loss of 0.73% for the day. On the previous day, the stock had closed at $4.11. The total traded volume of the day was 1,136,021 shares.
Synergy Pharmaceuticals Inc. (Synergy) is a biopharmaceutical company focused on the development of drugs to treat gastrointestinal (GI), disorders and diseases. The Companys platform technology is based on the naturally occurring human GI peptide, uroguanylin, a regulator of normal GI physiology. The Companys products include plecanatide, SP-333 and FV-100. The Companys lead product is plecanatide, a guanylate cyclase C (GC-C), receptor agonist, designed to treat GI disorders, primarily chronic idiopathic constipation (CIC), and constipation predominant irritable bowel syndrome (IBS-C). The Company is developing a second-generation GC-C receptor agonist, SP-333, for the treatment of opioid induced constipation (OIC), and for inflammatory bowel disease (IBD). FV-100 is an orally available nucleoside analog. The Companys subsidiaries include Synergy Advanced Pharmaceuticals, Inc., IgX, Ltd and ContraVir Pharmaceuticals, Inc.